Your browser doesn't support javascript.
loading
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
Young Han, Chae; Bedia, Jacob S; Yang, Wei-Lei; Hawley, Sarah J; Bergan, Lindsay; Hopper, Marika; Celestino, Joseph; Guo, Jing; Gornet, Terrie G; Soosaipillai, Antoninus; Yang, Hailing; Doskocil, Samantha D; Lokshin, Anna E; Handy, Beverly C; Diamandis, Eleftherios P; Moore, Richard G; Lu, Karen H; Lu, Zhen; Anderson, Karen S; Drescher, Charles W; Skates, Steven J; Bast, Robert C.
Afiliación
  • Young Han C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bedia JS; Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
  • Yang WL; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hawley SJ; Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Bergan L; Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Hopper M; Biodesign Institute, Arizona State University, Tempe, AZ, USA.
  • Celestino J; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Guo J; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gornet TG; Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Soosaipillai A; Lurenfeld-Tanebaum Research Institute (LTRI) Sinai Health System, Toronto, ON, Canada.
  • Yang H; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Doskocil SD; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lokshin AE; Departments of Pathology, Medicine, and Obstetrics and Gynecology, University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Handy BC; Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Diamandis EP; Lurenfeld-Tanebaum Research Institute (LTRI) Sinai Health System, Toronto, ON, Canada.
  • Moore RG; Department of Obstetrics and Gynecology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA.
  • Lu KH; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lu Z; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Anderson KS; Biodesign Institute, Arizona State University, Tempe, AZ, USA. Karen.Anderson.1@asu.edu.
  • Drescher CW; Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA, USA. cdresche@fredhutch.org.
  • Skates SJ; Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA. SSKATES@mgh.harvard.edu.
  • Bast RC; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rbast@mdanderson.org.
Br J Cancer ; 130(5): 861-868, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38195887
ABSTRACT

BACKGROUND:

Multiple antigens, autoantibodies (AAb), and antigen-autoantibody (Ag-AAb) complexes were compared for their ability to complement CA125 for early detection of ovarian cancer.

METHODS:

Twenty six biomarkers were measured in a single panel of sera from women with early stage (I-II) ovarian cancers (n = 64), late stage (III-IV) ovarian cancers (186), benign pelvic masses (200) and from healthy controls (502), and then split randomly (5050) into a training set to identify the most promising classifier and a validation set to compare its performance to CA125 alone.

RESULTS:

Eight biomarkers detected ≥ 8% of early stage cases at 98% specificity. A four-biomarker panel including CA125, HE4, HE4 Ag-AAb and osteopontin detected 75% of early stage cancers in the validation set from among healthy controls compared to 62% with CA125 alone (p = 0.003) at 98% specificity. The same panel increased sensitivity for distinguishing early-stage ovarian cancers from benign pelvic masses by 25% (p = 0.0004) at 95% specificity. From 21 autoantibody candidates, 3 AAb (anti-p53, anti-CTAG1 and annt-Il-8) detected 22% of early stage ovarian cancers, potentially lengthening lead time prior to diagnosis.

CONCLUSION:

A four biomarker panel achieved greater sensitivity at the same specificity for early detection of ovarian cancer than CA125 alone.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Autoanticuerpos Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Female / Humans Idioma: En Revista: Br J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Autoanticuerpos Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Female / Humans Idioma: En Revista: Br J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido